Conference Calls, New Appointments, Agreements, Pricing of Offerings and New Clinical Trials - Research Report on Abbott, Cubist, Pacific Biosciences, Synageva, and Oncothyreon

NEW YORK, September 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Pacific Biosciences of California (NASDAQ: PACB), Synageva BioPharma Corp. (NASDAQ: GEVA), and Oncothyreon Inc. (NASDAQ: ONTY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Abbott Laboratories Research Report

On September 25, 2013, Abbott Laboratories (Abbott) announced that it will release its Q3 2013 financial results on Wednesday, October 16, 2013, before the market opens. The Company informed that following the results release, it will also host an earnings conference call at 8:00 a.m. CT (9:00 a.m. ET) which will be webcast live through Abbott's Investor Relations website. In another announcement dated July 17, 2013, Abbott confirmed its guidance for full-year 2013 as it anticipates EPS to be within $1.98 to $2.04, in addition the Company expects full-year 2013 EPS from continuing operations to range from $1.39 to $1.45, including net specified items of approximately $0.59 per share. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/ABT]

Cubist Pharmaceuticals Inc. Research Report

On September 25, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that Kenneth J. Martin has been appointed to the Company's Board of Directors. According to the Company, since 2007, Mr. Martin has been serving as a member of the Board of WABCO Holdings, Inc. Ken Bate, Non-Executive Chairman of the Board of Directors of Cubist, said, "Ken Martin has an exceptional mix of global finance, industry and leadership expertise that will be a valued asset to Cubist, and we are thrilled to have him join our Board. Importantly, Ken's experience at Wyeth gives him an important perspective as Cubist begins its next, exciting chapter focused on global growth and continuing to drive significant shareholder value." The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/CBST]

Pacific Biosciences of California Research Report

On September 25, 2013, Pacific Biosciences of California (Pacific Biosciences) announced that it has entered into an agreement with Roche Diagnostics (Roche) to develop diagnostic products, including sequencing systems and consumables, based on Pacific Biosciences' Single Molecule, Real-Time (SMRT) technology. The Company informed that as per the agreement, Pacific Biosciences will develop and manufacture certain products for clinical use, which it will sell exclusively to Roche, who has worldwide rights to exclusively distribute these products in the field of human in vitro diagnostics. Pacific Biosciences further added that it will continue to market its current and future products for all fields outside of human in vitro diagnostics, including research, plant, animal, and applied markets. Dan Zabrowski, Head of the Sequencing Unit at Roche said, "We see great potential in Pacific Biosciences' sequencing technology for the development of future clinical sequencing applications. Sequencing will be a key technology in addressing the strong and growing demand for genetic and genomic solutions in the clinic. We are looking forward to this partnership to accelerate and support the transition of DNA sequencing into routine diagnostics through our joint development efforts."The Full Research Report on Pacific Biosciences of California - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/PACB]

Synageva BioPharma Corp. Research Report

On September 24, 2013, Synageva BioPharma Corp. (Synageva) announced the pricing of its previously announced underwritten public offering of common stock comprising of 2.75 million shares at a price of $56.63 per share. The Company stated in relation to this offering Synageva has granted to the underwriters a 30-day option to purchase 412,500 additional shares of common stock, which if exercised, will bring the total shares of its common stock offering to approximately 3.16 million shares. The Full Research Report on Synageva BioPharma Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/GEVA]

Oncothyreon Inc. Research Report

On September 25, 2013, Oncothyreon Inc. (Oncothyreon) announced that the biopharmaceutical division of Merck KGaA, Merck Serono has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (L-BLP25, formerly known as Stimuvax). According to the Company, Merck Serono is currently developing tecemotide under a license agreement with Oncothyreon and will conduct a Phase 3 trial called START2 for patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC), based on the outcome of the prior START trial.Dr. Annalisa Jenkins, Head of Global Drug Development and Medical for Merck Serono, said, "The START data delivered important insights that we believe justify further investigation in a new Phase 3 program. NSCLC is a devastating disease, and we are pleased to be able to continue supporting innovation in this important emerging field of immuno-oncology." The Full Research Report on Oncothyreon Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/ONTY]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by NamrataMaheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.InvestorsReports.com

SOURCE Investors' Reports